Athersys to Host Third Quarter Financial Results Call

Rhea-AI Summary

Athersys, Inc. (NASDAQ: ATHX) is set to release its third quarter 2021 financial results on November 15, 2021, at 4:00 PM ET. A conference call will follow at 4:30 PM ET to discuss the results. Shareholders can register for the call via the provided links to participate and can access a replay post-event through the company's website, available until November 22, 2021. Athersys focuses on developing its MultiStem® cell therapy for various critical care indications, as it continues to advance its clinical trials and strategic partnerships.

CLEVELAND--(BUSINESS WIRE)-- Athersys, Inc. (Nasdaq: ATHX) will release its third quarter 2021 financial results at approximately 4:00 PM Eastern Time on Monday, November 15, 2021, and will host a conference call shortly thereafter at 4:30 PM Eastern Time to review the results.

Members of the management team will host the call as follows:

Date		November 15, 2021
Time		4:30 p.m. (Eastern Time)
Live webcast registration		Webcast link
Phone registration		Call registration link

We encourage shareholders to listen using the webcast link above. If you would like to dial in using the phone to ask a question, please register for the conference call ahead of time using the call registration link above. Once registered, you will receive an email containing the toll-free number, a direct entry passcode and a registrant ID.

A replay of the event will be available on the webcast link at www.athersys.com under the investors' section approximately two hours after the call has ended. Shareholders may also call in for on-demand listening approximately three hours after the completion of the call until 11:59 PM Eastern Time on November 22, 2021, by dialing (800) 585-8367 or (416) 621-4642 and entering the conference code 6652068.

About Athersys

Athersys is a biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem^® cell therapy product, a patented, adult-derived "off-the-shelf" stem cell product, initially for disease indications in the neurological, inflammatory and immune, cardiovascular, and other critical care indications and has several ongoing clinical trials evaluating this potential regenerative medicine product. Athersys has forged strategic partnerships and a broad network of collaborations to further advance MultiStem cell therapy toward commercialization. Investors and others should note that we may post information about the Company on our website at www.athersys.com and/or on our accounts on Twitter, Facebook, LinkedIn or other social media platforms. It is possible that the postings could include information deemed to be material information. Therefore, we encourage investors, the media and others interested in the Company to review the information we post on our website at www.athersys.com and on our social media accounts. Follow Athersys on Twitter at www.twitter.com/athersys.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211018005661/en/

Ivor Macleod

Chief Financial Officer

Tel: (216) 431-9900

ir@athersys.com



Karen Hunady

Director of Corporate Communications and Investor Relations

Tel: (216) 431-9900

khunady@athersys.com



David Schull

Russo Partners, LLC

Tel: (212) 845-4271 or (858) 717-2310

David.schull@russopartnersllc.com

Source: Athersys, Inc.

FAQ

When will Athersys release its third quarter 2021 financial results?

Athersys will release its third quarter 2021 financial results on November 15, 2021.

What time is the Athersys conference call scheduled?

The Athersys conference call is scheduled for 4:30 PM ET on November 15, 2021.

How can I access the replay of the Athersys conference call?

The replay of the Athersys conference call will be available on their website approximately two hours after the call until November 22, 2021.

What is the focus area of Athersys's MultiStem® cell therapy?

Athersys's MultiStem® cell therapy is being developed for neurological, inflammatory, immune, cardiovascular, and other critical care indications.